-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: July 2009
House Energy and Commerce Committee Vote Marks Another Step Forward on Pathway to Biosimilars
House Energy and Commerce Committee Vote Marks Another Step Forward on Pathway to Biosimilars Strong bipartisan support for inclusion of pathway in health care reform legislation Washington, D.C. (July 31, 2009) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the approval of an amendment to create a regulatory pathway for biosimilars by the House Energy and Commerce Committee in today’s mark-up of the America’s Affordable Health Choices Act Read More >
Technology Transfer Symposium at BIO Investor Forum
Technology Transfer Symposium: Promoting Public-Private Collaboration for Innovation Wednesday October 28, 2009 7:30 am – 12 pm PT The Palace Hotel San Francisco, CA The Technology Transfer Symposium, held in conjunction with the BIO Investor Forum, will explore the domestic and international policy challenges for professionals in university, industry, and legal areas regarding the administration of technology transfer. This groundbreaking meeting will bring together stakeholder groups to discuss the challenges and opportunities of today’s Read More >
Clearing Another Hurdle on the Pathway to Biosimilars
The House Energy and Commerce Committee, by a vote of 47 to 11, overwhelmingly adopted an amendment creating a regulatory pathway for biosimilars that will provide 12 years of data exclusivity for innovative biologics. The strong bipartisan support for this amendment to the America’s Affordable Health Choices Act marks the second win this month for a fair and balanced approach to biosimilars market entry. This vote was a clear victory for patients. The ALS Association Read More >
Terminating the Myth—Setting the Record Straight
I was scrolling through a list of blogs that mention genetically modified (GM) foods when a post caught my eye. The post was on a blog called, “Jesus Lives,” and the author of the post, “Prophecy News Watch.” I’m always pleased to see groups discussing GM foods, however I think it’s important to get the facts right, particularly when I came to the following paragraph, “There are other issues — the question of the introduction Read More >
New Series: Biotechnology Companies at Forefront of Global Health Innovation – Post #1: GlaxoSmithKline & Alnylam Pharmaceuticals
On July 8 2009, GlaxoSmithKline (GSK) and Alnylam Pharmaceuticals, Inc. announced a patent pool to compile intellectual property (IP) to develop treatments for 16 tropical diseases as identified by the FDA including malaria, TB and Chagas, found in 49 Least Developed Countries as defined by the United Nations.
